091 Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23–receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the Phase 3, 
randomized, double-blind, placebo-controlled ICONIC-LEAD trial